CSCI Fundamental Analysis - COSCIENS BIOPHARMA INC

Fundamental Rating

Overall CSCI gets a fundamental rating of 3 out of 10. We evaluated CSCI against 23 industry peers in the Biotechnology industry. While CSCI seems to be doing ok healthwise, there are quite some concerns on its profitability. CSCI is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

CSCI had negative earnings in the past year.

CSCI had a negative operating cash flow in the past year.

In the past 5 years CSCI always reported negative net income.

CSCI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -62.48%, CSCI is in the better half of the industry, outperforming 60.87% of the companies in the same industry.

CSCI's Return On Equity of -293.43% is fine compared to the rest of the industry. CSCI outperforms 60.87% of its industry peers.

		Industry Rank	Sector Rank
ROA	-62.48%
ROE	-293.43%
ROIC	N/A

ROA(3y)-32.96%

ROA(5y)-24.63%

ROE(3y)-65.43%

ROE(5y)-50.16%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CSCI has a Gross Margin of 45.14%. This is in the better half of the industry: CSCI outperforms 78.26% of its industry peers.

CSCI's Gross Margin has improved in the last couple of years.

CSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	45.14%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-20.48%

GM growth 5Y19.79%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CSCI has more shares outstanding

Compared to 5 years ago, CSCI has more shares outstanding

CSCI has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -1.63, we must say that CSCI is in the distress zone and has some risk of bankruptcy.

CSCI's Altman-Z score of -1.63 is fine compared to the rest of the industry. CSCI outperforms 69.57% of its industry peers.

CSCI has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.39, CSCI is in line with its industry, outperforming 52.17% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.39
Debt/FCF	N/A
Altman-Z	-1.63

ROIC/WACCN/A

WACC7.47%

2.3 Liquidity

A Current Ratio of 3.47 indicates that CSCI has no problem at all paying its short term obligations.

CSCI's Current ratio of 3.47 is fine compared to the rest of the industry. CSCI outperforms 69.57% of its industry peers.

CSCI has a Quick Ratio of 3.03. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 3.03, CSCI is in the better half of the industry, outperforming 69.57% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.47
Quick Ratio	3.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CSCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.32%, which is quite impressive.

Looking at the last year, CSCI shows a very strong growth in Revenue. The Revenue has grown by 41.78%.

CSCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 80.53% yearly.

EPS 1Y (TTM)39.32%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.1%

Revenue 1Y (TTM)41.78%

Revenue growth 3Y21.84%

Revenue growth 5Y80.53%

Sales Q2Q%-20.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CSCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CSCI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

COSCIENS BIOPHARMA INC

TSX:CSCI (11/28/2025, 7:00:00 PM)

3.01

-0.28 (-8.51%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-11 2025-11-11

Earnings (Next)04-07 2026-04-07/amc

Inst Owners8.93%

Inst Owner ChangeN/A

Ins Owners1.45%

Ins Owner ChangeN/A

Market Cap9.57M

Revenue(TTM)9.05M

Net Income(TTM)-14.91M

Analysts82.86

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.75
P/FCF	N/A
P/OCF	N/A
P/B	1.34
P/tB	1.34
EV/EBITDA	N/A

EPS(TTM)-6.63

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-4.84

FCFYN/A

OCF(TTM)-4.41

OCFYN/A

SpS3.99

BVpS2.24

TBVpS2.24

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-62.48%
ROE	-293.43%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	45.14%
FCFM	N/A

ROA(3y)-32.96%

ROA(5y)-24.63%

ROE(3y)-65.43%

ROE(5y)-50.16%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-20.48%

GM growth 5Y19.79%

F-Score5

Asset Turnover0.38

Health

		Industry Rank	Sector Rank
Debt/Equity	0.39
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	75.06%
Cap/Sales	10.7%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.47
Quick Ratio	3.03
Altman-Z	-1.63

F-Score5

WACC7.47%

ROIC/WACCN/A

Cap/Depr(3y)43.14%

Cap/Depr(5y)N/A

Cap/Sales(3y)7.47%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)39.32%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.1%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)41.78%

Revenue growth 3Y21.84%

Revenue growth 5Y80.53%

Sales Q2Q%-20.74%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y31.07%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y27.44%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y34.02%

OCF growth 3YN/A

OCF growth 5YN/A

COSCIENS BIOPHARMA INC / CSCI.CA FAQ

What is the fundamental rating for CSCI stock?

ChartMill assigns a fundamental rating of 3 / 10 to CSCI.CA.

What is the valuation status of COSCIENS BIOPHARMA INC (CSCI.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to COSCIENS BIOPHARMA INC (CSCI.CA). This can be considered as Overvalued.

How profitable is COSCIENS BIOPHARMA INC (CSCI.CA) stock?

COSCIENS BIOPHARMA INC (CSCI.CA) has a profitability rating of 2 / 10.

How financially healthy is COSCIENS BIOPHARMA INC?

The financial health rating of COSCIENS BIOPHARMA INC (CSCI.CA) is 4 / 10.

COSCIENS BIOPHARMA INC (CSCI.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

COSCIENS BIOPHARMA INC / CSCI.CA FAQ

What is the fundamental rating for CSCI stock?

What is the valuation status of COSCIENS BIOPHARMA INC (CSCI.CA) stock?

How profitable is COSCIENS BIOPHARMA INC (CSCI.CA) stock?

How financially healthy is COSCIENS BIOPHARMA INC?